Pharmaceutical Industry 3 – 9 Aug: Ft Atsena Therapeutics and Infinitopes
- Atsena Therapeutics has secured European orphan designation for two gene therapy candidates targeting rare inherited retinal diseases.
- Infinitopes has dosed the first patient with ITOP1, its lead investigational therapeutic cancer vaccine.
Two emerging biotechnology companies have reached significant milestones in the development of advanced therapies for serious and difficult-to-treat diseases.
Atsena Therapeutics has received orphan designation from the European Medicines Agency for two clinical-stage gene therapy candidates targeting inherited retinal diseases. Meanwhile, Infinitopes has moved its Precision Immunomics platform into human clinical testing with the first patient dosed in a study of its lead therapeutic cancer vaccine.
Although the programmes address very different diseases, the announcements reflect a common direction within the pharmaceutical industry. Developers are increasingly using precision medicine, genetic technologies and advanced immunology to pursue conditions for which existing treatment options remain limited or entirely absent.
Atsena secures European backing for two gene therapy programmes
Atsena Therapeutics has been granted orphan designation by the European Medicines Agency for ATSN-101 and ATSN-201.
ATSN-101 is being developed for Leber congenital amaurosis 1, while ATSN-201 is intended to treat X-linked retinoschisis. Both are rare inherited retinal diseases that can cause substantial and progressive vision impairment.
The European designation provides Atsena with several development incentives as the company advances both programmes through global pivotal trials. These benefits include reduced regulatory fees, access to protocol assistance and up to 10 years of market exclusivity in the European Union following approval.
European orphan designation is reserved for therapies intended to treat rare conditions that are life-threatening or chronically debilitating. Developers must also demonstrate either that no satisfactory treatment exists or that the proposed therapy could provide a significant benefit to patients.
Atsena’s chief executive said receiving the designation for both candidates underlined the substantial unmet needs facing patients who currently have no available treatment options.
The executive added that the rapid enrolment of the ATSN-201 pivotal trial, combined with plans to begin a global pivotal study of ATSN-101 later in 2026, means the company is closer than ever to delivering gene therapies that could change the trajectory of inherited retinal diseases for patients in the United States, Europe and other international markets.
LIGHTHOUSE phase 3 cohort gathers pace
Atsena dosed the first patient in the pivotal phase 3 cohort of its LIGHTHOUSE trial in June 2026.
The study is evaluating ATSN-201 in people with X-linked retinoschisis, a genetic eye condition that primarily affects the retina and can lead to impaired vision from an early age.
Approximately 76 patients aged six years and older are expected to participate in the pivotal study. Microperimetry, which measures retinal sensitivity and visual function at specific points across the retina, will serve as the primary endpoint. A 52-week readout is planned.
According to the company, enrollment is progressing ahead of expectations, providing positive momentum for a programme addressing a disease with no currently approved treatment capable of correcting its underlying genetic cause.
ATSN-201 has already demonstrated evidence of activity during the completed phase 1/2 portion of LIGHTHOUSE. Most patients treated in the earlier stage showed improvements in retinal structure and visual function.
Follow-up data now extend to two years for some participants, with the therapy continuing to demonstrate a favourable safety profile. These longer-term observations will be important as Atsena seeks to establish whether the improvements seen in earlier testing can be reproduced across a larger and more diverse patient population.
The programme has also received several regulatory designations from the US Food and Drug Administration, including Orphan Drug and Fast Track designations. These measures are designed to support and potentially accelerate the development of treatments for serious conditions with unmet medical needs.
ATSN-101 prepares for global pivotal testing
Atsena is also preparing to begin a global pivotal phase 3 trial of ATSN-101 later in 2026.
The candidate is being developed for Leber congenital amaurosis 1, an inherited retinal disorder that can cause severe visual impairment or blindness from infancy or early childhood.
The ATSN-101 programme is being advanced in collaboration with Japanese pharmaceutical company Nippon Shinyaku. Its European orphan designation adds another regulatory incentive as the partners prepare to move the candidate into late-stage clinical development.
Like ATSN-201, ATSN-101 has received Orphan Drug and Fast Track designations from the FDA.
The combination of European and American regulatory support places Atsena in a stronger position to coordinate development across major international markets. It also reflects growing regulatory recognition of the need for innovative therapies capable of addressing the genetic basis of rare ophthalmic diseases.
Infinitopes takes Precision Immunomics platform into the clinic
In a separate clinical development milestone, Infinitopes has dosed the first patient with ITOP1, its lead investigational therapeutic cancer vaccine.
The treatment is being evaluated in the VISTA study, marking the first clinical assessment of Infinitopes’ Precision Immunomics platform.
The company’s approach combines immunopeptidomic antigen discovery with engineered viral vector technology. It is designed to identify tumour antigens that are naturally presented by cancer cells and capable of triggering durable anti-tumour T-cell responses.
Rather than focusing solely on theoretical or predicted cancer targets, the platform seeks to determine which antigens are genuinely displayed by patients’ tumours. These targets can then be delivered through viral vectors engineered to stimulate a focused and sustained immune response.
Infinitopes believes the model could support the development of precise, off-the-shelf cancer therapies across a range of solid tumours.
VISTA investigates vaccination before cancer surgery
VISTA is a multicentre, randomised, double-blind, placebo-controlled phase 1/2a clinical trial being conducted in collaboration with the University of Oxford.
The study will evaluate ITOP1 in patients with newly diagnosed, surgically resectable oesophageal adenocarcinoma and gastro-oesophageal junction adenocarcinoma.
One of the most notable aspects of the trial is the timing of treatment. Many therapeutic cancer vaccine strategies have historically been investigated following surgery, when the primary tumour has already been removed.
VISTA will instead assess the vaccine while the primary tumour remains in place. Investigators hope this neoadjuvant setting will offer a stronger opportunity to prime the immune system against antigens associated with the patient’s cancer.
The current standard of care for resectable disease includes neoadjuvant FLOT and durvalumab chemoimmunotherapy, followed by surgery and adjuvant chemoimmunotherapy.
Within VISTA, ITOP1 is administered between chemoimmunotherapy and surgery, with treatment delivered both before and after oesophagectomy. This design will allow researchers to examine vaccine-induced immune responses at several stages of first-line treatment.
The trial’s chief investigator described the dosing of the first patient as an important landmark for both the programme and the wider therapeutic cancer vaccine field.
The investigator said the neoadjuvant setting provides a valuable opportunity to study immune activity while the primary tumour is still present. VISTA is designed to establish whether the approach can safely generate meaningful anti-tumour immunity and potentially delay recurrence following standard treatment and surgery.
First safety data expected in early 2027
The phase 1 safety lead-in will initially recruit eight participants. Subject to the results of this stage, the study will progress into a randomised, placebo-controlled phase 2a section involving a further 52 patients.
Initial safety and immunological findings are expected in early 2027.
Infinitopes’ co-founder, president and chief medical officer described entering clinical development as a defining milestone in the creation of future medicines.
For the company, VISTA represents the first human evaluation of an integrated model combining Precision Immunomics target discovery with established viral vector technologies.
By identifying antigens naturally presented by patients’ tumours and delivering them using vectors designed to generate durable T-cell immunity, Infinitopes believes it could build a broader pipeline of therapeutic vaccine programmes for multiple solid tumour types.
The early clinical data will be closely watched. While therapeutic cancer vaccines have long held promise, the field has faced challenges in identifying the correct targets, generating sufficiently strong immune responses and demonstrating a meaningful effect on patient outcomes.
Infinitopes is attempting to address those challenges by combining more precise antigen selection with a delivery system intended to produce lasting immunity.
Impact on pharmaceutical manufacturing and production
The progress made by Atsena Therapeutics and Infinitopes also carries important implications for pharmaceutical manufacturing and production.
Gene therapies and viral vector-based cancer vaccines require highly specialised production systems that differ considerably from those used for conventional tablets or injectable medicines. Manufacturers must maintain tight control over vector quality, potency, purity, sterility and genetic consistency, often while working with relatively small patient populations.
As Atsena’s programmes move into global pivotal trials, the company and its manufacturing partners will need to demonstrate that their production processes can reliably support larger clinical studies and, eventually, commercial supply.
This includes establishing scalable vector manufacturing, validated analytical testing, controlled storage conditions and dependable international distribution.
Infinitopes will face similar demands as ITOP1 progresses. The company’s off-the-shelf approach may offer advantages over fully personalised cancer vaccines, but consistent antigen design, vector production and batch reproducibility will remain central to successful development.
The wider effect could be increased investment in advanced therapy manufacturing capacity, specialist workforce skills and flexible production facilities.
Contract development and manufacturing organisations with expertise in adeno-associated viral vectors, engineered viral platforms and complex biological testing are likely to become increasingly important.
These programmes also demonstrate why manufacturability must be considered early in clinical development. A therapy may show strong scientific promise, but its commercial viability will depend on whether it can be produced safely, consistently and at a scale that supports patient access across multiple markets.
Conclusion
The latest developments from Atsena Therapeutics and Infinitopes highlight two distinct but equally ambitious areas of pharmaceutical innovation.
Atsena’s European orphan designations strengthen the regulatory position of ATSN-101 and ATSN-201 as both gene therapy candidates move towards pivotal clinical evaluation.
With ATSN-201 enrollment progressing ahead of expectations and the ATSN-101 phase 3 programme scheduled to begin later in 2026, the company is entering an important period of late-stage development.
Infinitopes, meanwhile, has crossed the threshold into clinical testing with ITOP1. The VISTA study will provide the first human evidence of whether its Precision Immunomics platform can safely generate meaningful and durable anti-tumour immune responses within the demanding setting of oesophageal and gastro-oesophageal junction cancers.
Both announcements reflect the pharmaceutical industry’s continuing shift towards treatments built around the underlying biology of disease.
The clinical, regulatory and manufacturing challenges remain considerable, but the potential rewards are equally significant: new treatment possibilities for patients whose options are currently limited, and new platforms capable of supporting future medicines across rare diseases and cancer.
News Credits:
Atsena gains EMA orphan status for two gene therapies
Vista trial begins dosing in precision cancer vaccine study
Things you may also like: